Principia Biopharma Inc.

Principia Biopharma Inc. is a clinical-stage biopharmaceutical company that specializes in developing innovative therapies for immune-mediated diseases. The company's Tailored Covalency® technology platform allows for the creation of small molecule drugs that selectively target specific disease-causing proteins. PRN1008, the company's lead product candidate, is a reversible covalent inhibitor of Bruton's tyrosine kinase (BTK) that is being developed to treat autoimmune diseases such as pemphigus, immune thrombocytopenia, and multiple sclerosis. Principia is also developing a pipeline of other small molecule drugs that target various immune-mediated diseases, including inflammatory bowel disease, rheumatoid arthritis, and lupus. The company's team of experienced scientists and drug developers is committed to advancing its mission of improving the lives of patients with immune-mediated diseases. Principia is headquartered in South San Francisco, California, with additional offices in San Diego, California, and Cambridge, Massachusetts.